As companies with lung cancer immunotherapies process the small level detail they received on the outcome of August's PBAC meeting at which the committee considered simplifying their reimbursement, AstraZeneca has announced new and positive results from its yet-to-be-listed IMFINZI (durvalumab). …
Latest Video
New Stories
-
George Tambassis: 'Making our position clear to Government in no uncertain terms'
February 25, 2020 - - Latest News -
Chris Bowen: 'Timeline for the review raises serious questions'
February 25, 2020 - - Latest News -
A 'piecemeal' review in response to a 'piecemeal' approach to policy?
February 25, 2020 - - Comment -
Companies make WGEA employer of choice list
February 25, 2020 - - Latest News -
Expansion on the agenda for Biointelect
February 25, 2020 - - Latest News -
Greg Hunt: More time for review if stakeholders make the case
February 25, 2020 - - Latest News -
STA 'dismayed and frustrated' over rejection of tumour profiling test
February 24, 2020 - - Latest News